
|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar
Author(s)Tom Brody
By Tom Brody, DNAX Research Institute, pp. 38-42. Early sale or offers to sell an invention may result in the rejection of a patent application under 35 U.S.C. 102(b). Such a rejection is called "the on-sale bar," and it permanently prevents patenting of an invention.
Advertisement
Articles in this issue
over 23 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 23 years ago
The Immunogenicity of Therapeutic Proteinsover 23 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 23 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5